Recombinant Anti-RCAS1 Antibody [rEBAG9/7264] (A315544)

Anti-RCAS1 Antibody [rEBAG9/7264]

Recombinant mouse monoclonal [rEBAG9/7264] antibody to RCAS1.

EBAG9, also known as RCAS1, is an estrogen-transcribed protein. Soluble and membranous RCAS1 proteins may play a role in the immune escape of tumor cells by promoting T lymphocyte inhibition of growth and apoptosis. RCAS1 is expressed in a wide variety of cancers, including uterine, ovarian, and lung cancer cells, and acts as a ligand for a putative receptor present on peripheral lymphocytes. RCAS1 is highly expressed not only in cancer cells but also in non-tumor bile duct cells subject to immune attack. RCAS1 inhibits the in vitro growth of receptor-expressing cells and induces apoptosis, contributing to the ability of tumor cells to evade host immune surveillance. High expression of RCAS1 significantly correlates with tumor progression and with poor outcome for many cancer patients.

MCF-7, Jurkat or HEK-293 cell lysates. Human skeletal muscle tissue.

IHC: 1-2 µg/ml

Human

Recombinant full-length human EBAG9 protein.

Mouse

Monoclonal

rEBAG9/7264

IgG1

Unconjugated

Protein A/G chromatography.

200 µg/ml

32 kDa

Liquid

Supplied in 10mM Phosphate Buffered Saline with 0.05% BSA and 0.05% Sodium Azide.

Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

BAG9, Cancer associated surface antigen, Cancer associated surface antigen RCAS1, Cancer-associated surface antigen RCAS1, EB9, EBAG 9, EBAG9, Estrogen receptor binding fragment associated gene 9 protein, Estrogen receptor binding site associated antigen 9, estrogen receptor binding site associated, antigen, 9, Estrogen receptor-binding fragment-associated gene 9 protein, PDAF, RCAS 1, RCAS1_HUMAN, Receptor binding cancer antigen expressed on SiSo cells, Receptor-binding cancer antigen expressed on SiSo cells